NO20091330L - Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav - Google Patents

Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav

Info

Publication number
NO20091330L
NO20091330L NO20091330A NO20091330A NO20091330L NO 20091330 L NO20091330 L NO 20091330L NO 20091330 A NO20091330 A NO 20091330A NO 20091330 A NO20091330 A NO 20091330A NO 20091330 L NO20091330 L NO 20091330L
Authority
NO
Norway
Prior art keywords
derived peptides
methods
peptides
pharmacological
cupredoxin
Prior art date
Application number
NO20091330A
Other languages
English (en)
Norwegian (no)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20091330L publication Critical patent/NO20091330L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20091330A 2006-09-11 2009-03-31 Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav NO20091330L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84338806P 2006-09-11 2006-09-11
PCT/US2007/078136 WO2008033820A2 (fr) 2006-09-11 2007-09-11 Modifications de peptides dérivés de la cuprédoxine et procédés d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
NO20091330L true NO20091330L (no) 2009-06-05

Family

ID=39184502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091330A NO20091330L (no) 2006-09-11 2009-03-31 Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav

Country Status (14)

Country Link
US (2) US10005821B2 (fr)
EP (1) EP2061487A4 (fr)
JP (2) JP2010502765A (fr)
KR (1) KR20090059148A (fr)
CN (1) CN101600447A (fr)
AU (1) AU2007296614A1 (fr)
BR (1) BRPI0715027A2 (fr)
CA (1) CA2663188A1 (fr)
IL (1) IL197501A0 (fr)
MX (1) MX2009002612A (fr)
NO (1) NO20091330L (fr)
RU (1) RU2009113562A (fr)
SG (1) SG174108A1 (fr)
WO (1) WO2008033820A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
JP2008515428A (ja) 2004-10-07 2008-05-15 チャクラバルティ、アナンダ キュプレドキシンに由来する輸送因子及びそれを使用する方法
US8232244B2 (en) 2007-02-08 2012-07-31 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US8158574B2 (en) 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US9968685B2 (en) * 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
AU2006269879A1 (en) 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
AU2007307254A1 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
JP2010511408A (ja) 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
CA2725227A1 (fr) 2008-05-06 2009-11-12 Asim Kumar Debnath Peptides antiviraux penetrant dans les cellules
CN103937705B (zh) * 2014-03-10 2016-03-16 赵晗 一株罕见无色杆菌及其在去除重金属离子中的应用
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
EP1173223A2 (fr) 1999-04-30 2002-01-23 Slil Biomedical Corporation Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7556810B2 (en) * 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
JP4881536B2 (ja) 2001-02-15 2012-02-22 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 細胞死を調節する細胞障害性因子
CA2506318C (fr) 2002-11-15 2011-07-12 Chiron Srl Proteines de surface inattendues sur le meningocoque
CN1506375A (zh) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
US20040132966A1 (en) 2002-12-30 2004-07-08 Miranda Leslie Philip Backbone anchored thioester and selenoester generators
AU2003220380A1 (en) 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
GB0321937D0 (en) 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
JP2008515428A (ja) 2004-10-07 2008-05-15 チャクラバルティ、アナンダ キュプレドキシンに由来する輸送因子及びそれを使用する方法
CA2594151C (fr) 2004-12-07 2013-02-19 Applied Nanosystems B.V. Methodes de production et de secretion de peptides modifies
AU2006269879A1 (en) * 2005-07-19 2007-01-25 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof

Also Published As

Publication number Publication date
WO2008033820A2 (fr) 2008-03-20
IL197501A0 (en) 2011-08-01
US10005821B2 (en) 2018-06-26
WO2008033820A3 (fr) 2008-12-18
EP2061487A2 (fr) 2009-05-27
US20180319848A1 (en) 2018-11-08
JP2014193886A (ja) 2014-10-09
SG174108A1 (en) 2011-09-29
BRPI0715027A2 (pt) 2013-05-28
WO2008033820A8 (fr) 2009-07-30
CN101600447A (zh) 2009-12-09
KR20090059148A (ko) 2009-06-10
US20100267608A1 (en) 2010-10-21
US10590177B2 (en) 2020-03-17
AU2007296614A1 (en) 2008-03-20
CA2663188A1 (fr) 2008-03-20
EP2061487A4 (fr) 2009-12-02
JP2010502765A (ja) 2010-01-28
RU2009113562A (ru) 2010-10-20
MX2009002612A (es) 2009-12-15

Similar Documents

Publication Publication Date Title
NO20091330L (no) Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav
MX2019001198A (es) Activadores de moleculas pequeñas de funcion de la enzima parkin.
WO2018049152A8 (fr) Dérivés de pyrazolopyrimidine en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AU2018236800B2 (en) DNA-PK inhibitors
EP3736294A3 (fr) Blocage de cd73
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
EA201190178A1 (ru) Замещённые нуклеозидные и нуклеотидные аналоги
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
WO2012037155A3 (fr) Inhibiteurs des tyrosines kinases
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
DK2137301T3 (da) Adenovirus med mutationer i det endoplasmatiske reticulums retentionsdomæne for E3-19K-proteinet samt deres anvendelse ved cancerbehandling
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MX2009005300A (es) Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
WO2010011343A3 (fr) Procédés de traitement d’affections virales
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
GB2495885A (en) Combination pharmaceutical composition and methods of treating genitourinary system disorders
EA201390217A1 (ru) Способы лечения алкогольной интоксикации, расстройств, связанных с употреблением алкоголя, и злоупотребления алкоголем, которые включают введение дигидромирицетина
WO2013016278A3 (fr) Modulateurs de voies de signalisation antivirales et usages thérapeutiques associés
IN2012DN00592A (fr)
WO2010096681A3 (fr) Modifications de peptides issus de la cuprédoxine et leurs procédés d'utilisation
WO2020055906A8 (fr) Procédés de traitement du cancer par inhibition de l'enzyme de conjugaison de l'ubiquitine e2 k (ube2k)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application